🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)SURMOUNT-OSA: tirzepatide and sleep apnea AHI reduction

SURMOUNT-OSA: tirzepatide and sleep apnea AHI reduction

SleepDoc_PDX Fri, Jun 5, 2026 at 7:06 AM 12 replies 308 viewsPage 1 of 3
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Jun 5, 2026 at 7:06 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

The apnoea data is some of the strongest non-weight evidence in the class. SURMOUNT-OSA showed large reductions in apnoea-hypopnoea index on tirzepatide, with a meaningful fraction of participants improving enough to change their treatment category. Mechanistically it is upper-airway fat and reduced abdominal load rather than anything neurological, which is why the effect tracks weight loss closely.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

So the question, as narrowly as I can put it: what people did about re-titration, because feeling better is not the same as a study saying you are better. Happy to be told the question itself is wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
34 4pete_nash, hank_denver, carlos_SATX and 31 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 5, 2026 at 8:13 AM#2
SleepDoc_PDX said:
The apnoea data is some of the strongest non-weight evidence in the class.

True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.

Last edited: Jun 5, 2026 at 1:13 PM
33 3tyler_CSCS, VanRx_Mike, steve_okc and 30 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Jun 5, 2026 at 9:20 AM#3
SleepDoc_PDX said:
The apnoea data is some of the strongest non-weight evidence in the class.

I read this differently from SleepDoc_PDX, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

Ask again with the specifics and you will get a better answer than this one.

32 2AttorneyGrant, DebRD_ATL, KristenIndy and 29 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Jun 5, 2026 at 10:28 AM#4

Answering the narrow version, because the broad one does not have a single answer. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.

Last edited: Jun 5, 2026 at 1:28 PM
31 1lori_vegas, Dr.PulmRoch, maya_sedona and 28 others
Reply Quote Save Share Report
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Jun 5, 2026 at 4:53 PM#5
Dr.GutHealth said:
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of…

Second this. Nothing to add that would improve it.

30 0Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 27 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register